(Total Views: 492)
Posted On: 11/30/2024 2:54:13 PM
Post# of 148863
Re: Evil Rabbit #148351
Tyler Blok promoted on September 27, 2024:
"Tyler Blok. Mr. Blok has served as the Company’s in-house legal counsel since July 25, 2022, and was appointed by the Board as Executive Vice President of Legal Affairs effective August 15, 2023, and as Chief Legal Officer on September 27, 2024."
Incentive compensation paid out in September 2024. Exact date in September was not provided:
"In September 2024, the committee approved the payment of non-equity incentive compensation to Tyler Blok in the amount of $100,000, representing approximately 75% of the target cash incentive he was eligible for in fiscal year 2024, based on the level of achievement of his assigned performance goals. The goals related to the lifting of the Food and Drug Administration’s clinical hold on clinical studies of leronlimab and the resolution of certain significant disputes with third parties on terms materially favorable to the Company. The committee determined that a fourth performance goal, relating to obtaining a material strategic partnership or licensing transaction, was not met."
https://www.cytodyn.com/investors/sec-filings...load=false
"Tyler Blok. Mr. Blok has served as the Company’s in-house legal counsel since July 25, 2022, and was appointed by the Board as Executive Vice President of Legal Affairs effective August 15, 2023, and as Chief Legal Officer on September 27, 2024."
Incentive compensation paid out in September 2024. Exact date in September was not provided:
"In September 2024, the committee approved the payment of non-equity incentive compensation to Tyler Blok in the amount of $100,000, representing approximately 75% of the target cash incentive he was eligible for in fiscal year 2024, based on the level of achievement of his assigned performance goals. The goals related to the lifting of the Food and Drug Administration’s clinical hold on clinical studies of leronlimab and the resolution of certain significant disputes with third parties on terms materially favorable to the Company. The committee determined that a fourth performance goal, relating to obtaining a material strategic partnership or licensing transaction, was not met."
https://www.cytodyn.com/investors/sec-filings...load=false
(3)
(0)Scroll down for more posts ▼
